ELU001 for Ovarian and Endometrial Cancers

Recruiting at 17 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Elucida Oncology

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing ELU001, a new drug that targets advanced cancers by delivering cancer-fighting chemicals directly to the cancer cells. It focuses on adults with difficult-to-treat cancers that overproduce a specific protein and have no other treatment options. The drug acts like a guided missile, aiming to kill cancer cells while sparing healthy ones.

Research Team

Eliel Bayever, MBBCh, MRCP

Principal Investigator

Elucida Oncology, Inc.

Eligibility Criteria

Adults with advanced, recurrent or refractory tumors that have high levels of a protein called folate receptor alpha (FRα) and are sensitive to certain chemotherapy drugs. Participants must be in fairly good health, not pregnant or planning to become so, have recovered from any surgeries, and lack other treatment options.

Inclusion Criteria

I have been diagnosed with a specific type of cancer such as ovarian, colorectal, or lung cancer.

I can take care of myself and am up and about more than half of my waking hours.

My cancer can be measured by standard tests or, if not, it still follows certain criteria.

Exclusion Criteria

I have not taken treatments targeting the protein folate receptor alpha.

You have a detectable viral load for HIV, hepatitis B, or hepatitis C.

If you are pregnant

Treatment Details

Interventions

• ELU001 (Topoisomerase I inhibitors)

Trial Overview ELU001 is being tested; it's a new type of drug-conjugate designed to target cancer cells overexpressing FRα. It combines a chemotherapy agent with folic acid analogs linked to a carrier particle, aiming for precise delivery to the tumor while sparing healthy tissue.

Participant Groups

Group I: ELU001 Experimental Treatment 1 Intervention

Dose Escalation: Escalating doses of ELU001 Dose Expansion: Recommended Dose for Expansion (or RP2D)

Who Is Running the Clinical Trial?

Elucida Oncology

Lead Sponsor

Trials

3

Recruited

90+